Urinary biomarkers to mitigate diagnostic delay in bladder cancer during the COVID-19 era

The COVID-19 pandemic has resulted in a substantial increase in waiting times for cystoscopies, prompting concerns of delayed diagnoses and substandard surveillance of bladder cancer. Expanding the role of urinary biomarkers in diagnostic and surveillance pathways could be a strategy to address this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Kenrick, Vinnakota, Krishna, Sharma, Anand, Kelly, John, Dasgupta, Prokar, Vasdev, Nikhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745709/
https://www.ncbi.nlm.nih.gov/pubmed/33335321
http://dx.doi.org/10.1038/s41585-020-00419-z
Descripción
Sumario:The COVID-19 pandemic has resulted in a substantial increase in waiting times for cystoscopies, prompting concerns of delayed diagnoses and substandard surveillance of bladder cancer. Expanding the role of urinary biomarkers in diagnostic and surveillance pathways could be a strategy to address this problem, and several novel biomarkers have shown promise for this purpose.

Ejemplares similares